Array BioPharma appoints vp of clinical development

Bengt Berstrom has joined biopharmaceutical firm Array BioPharma as vp of clinical development.

Bengt Berstrom has joined biopharmaceutical firm Array BioPharma as vp of clinical development.

With more than 17 years" working in the pharmaceutical industry, Dr Bergstrom will lead Array's clinical science and drug safety activities for its growing pipeline of targeted small molecule drugs to treat cancer and inflammatory diseases.

"Bengt's expertise in advancing cancer and inflammation therapeutics, including oral cancer therapies such as Xeloda, will be a competitive advantage for Array as we progress our five wholly owned drugs in human clinical development," said chief executive Robert Conway.

Prior to joining Array, Dr Bergstrom held various roles Hoffmann-La Roche, most recently as clinical science leader in oncology drug development.

Dr Bergstrom studied at the University of Lund in Sweden where he received his MD and PhD.




You may also like

Research & Development

Array BioPharma closes cancer drug deal with Pierre Fabre

Array may receive up to US$425m in agreement to develop novel oncology products
Regulatory

Anticancer agent – binimetinib

The new generation of genetically targeted anticancer agents is being developed for melanoma patients with specific mutations
Research & Development

Array Biopharma and Genentech to progress ChK-1 programme

Genentech will pay US$28m upfront payment to Array
Research & Development

Array BioPharma signs strategic oncology collaboration

Agreement with Novartis will advance aim to become integrated, commercial-stage biopharma company
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

The path to commercial allogeneic iPSC therapies

The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Research & Development

The IND advantage: why early derisking is a strategic imperative for complex biologics

As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Research & Development

Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies

Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
Subscribe now